Edition:
United Kingdom

Veru Inc (VERU.OQ)

VERU.OQ on NASDAQ Stock Exchange Capital Market

1.32USD
20 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.32
Open
$1.31
Day's High
$1.34
Day's Low
$1.29
Volume
24,342
Avg. Vol
20,016
52-wk High
$2.99
52-wk Low
$0.90

Latest Key Developments (Source: Significant Developments)

Veru Inc - On Jan 4, 2018, Daniel Haines, CFO, Informed Co That He Was Resigning ‍​
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Veru Inc ::VERU INC - ON JAN 4, 2018, DANIEL HAINES, CFO, INFORMED CO THAT HE WAS RESIGNING ‍​.VERU SAYS ‍HAINES' DUTIES AS CFO WERE ASSIGNED EFFECTIVE JAN 4, 2018 TO MICHELE GRECO​ - SEC FILING.  Full Article

Veru reports Q4 Loss Per Share $0.10
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Veru Inc ::VERU REPORTS FISCAL 2017 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.10.Q4 REVENUE $3.7 MILLION VERSUS $3.6 MILLION.  Full Article

Veru Acquires Novel Proprietary Formulation For Overactive Bladder
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Veru Inc ::VERU ACQUIRES NOVEL PROPRIETARY FORMULATION FOR OVERACTIVE BLADDER.VERU PLANS TO BEGIN SOLIFENACIN DRG BIOEQUIVALENCE STUDY IN 2018 AND TO FILE NDA IN 2019.‍UNDER TERMS OF AGREEMENT WITH CAMARGO, VERU PAID AN UNDISCLOSED UPFRONT FEE TO ACQUIRE ASSET​.UNDER TERMS, VERU TO PAY UNDISCLOSED MILESTONE FEES UPON SUCCESSFUL CLINICAL DEVELOPMENT, LOW SINGLE DIGIT ROYALTY UPON COMMERCIAL SALES​.FDA ‍CONFIRMED IN A MEETING WITH CO THAT REGULATORY APPROVAL FOR SOLIFENACIN DRG WILL REQUIRE A SINGLE BIOEQUIVALENCE STUDY​.  Full Article

Veru announces Tamsulosin drs bioequivalence clinical trial results
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Veru Inc :Veru announces Tamsulosin Drs bioequivalence clinical trial results.Veru Inc - ‍Expected timing of additional formulation adjustment should allow us to remain on track for a pre-NDA meeting in early 2018​.  Full Article

Veru files for mixed shelf of up to $50 million
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Veru Inc :Files for mixed shelf of up to $50 million - SEC filing‍​.  Full Article

FEMALE HEALTH COMPANY REPORTS Q1 LOSS PER SHARE $0.04
Thursday, 9 Feb 2017 

Female Health Co : THE FEMALE HEALTH COMPANY / VERU HEALTHCARE REPORTS FISCAL 2017 FIRST-QUARTER FINANCIAL RESULTS . Q1 LOSS PER SHARE $0.04 . Q1 REVENUE $3.2 MILLION . HAVE REQUESTED A PRE-IND MEETING WITH FDA FOR APP-944 . "MAY CONTINUE TO EXPERIENCE CHALLENGES FOR UNIT SALES OF FC2 IN GLOBAL PUBLIC SECTOR FOR REMAINDER OF FISCAL 2017" ."CURRENTLY SEEING PRESSURE ON SPENDING FOR FC2 BY LARGE GLOBAL AGENCIES AND DONOR GOVERNMENTS IN DEVELOPED WORLD".  Full Article

The Female Health Company/Veru Healthcare reports Q4 loss per share $0.06
Monday, 12 Dec 2016 

Female Health Co : The Female Health Company/ Veru Healthcare reports fiscal 2016 fourth-quarter, full-year financial results . Q4 loss per share $0.06 .Q4 revenue $3.6 million.  Full Article

Female Health and Aspen Park announce FDA clears pathway for expedited development of proprietary drug
Wednesday, 17 Aug 2016 

Female Health Co : Female Health Company and Aspen Park Pharmaceuticals announce FDA clears pathway for expedited development of proprietary drug . FDA also agreed with plans to conduct a single bioequivalence study to support filing of a NDA . Special meeting of FHC shareholders is scheduled for September 20, 2016 to approve matters relating to proposed merger .Intend to initiate a three week bioequivalence study in Q4 of this year and submit a NDA in 2017.  Full Article

The Female Health Company reports fiscal 2016 third quarter results
Thursday, 28 Jul 2016 

Female Health Co : The Female Health Company reports fiscal 2016 third quarter and first nine months operating results . Q3 earnings per share $0.02 .Q3 revenue $5.561 million.  Full Article

BRIEF-Veru Q1 Loss Per Share $0.08

* REMAIN ON TRACK TO FILE WITH FDA COMPANY'S FIRST NDA FOR TAMSULOSIN DRS IN 2018